The Purine and Pyrimidine Metabolism in Lactating Dairy Cows
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Annotation-1 Annotation-1
Annotation-1 Baseline Resuscitation Normal Saline Resuscitation PFP Shock Annotation-1 Aminoacids Arginine and proline metabolism Carnitine and fatty acid metabolsim Glutamate metabolism Glycerophospholipid biosynthesis Glycolysis and sugars GSH homeostasis GSH homeostasis/Glyoxlate Hexosamine Indole and Tryptophan Nucleotides Other Panthothenate metabolism Pentose Phosphate Pathway Serine biosynthesis and one-carbon metabolism Signaling Sulfur metabolism TCA cycle urea cycle relative row min row max Baseline_14 Baseline_16 Baseline_13 Baseline_15 Baseline_22 Baseline_2 Baseline_12 Baseline_3 Baseline_4 Baseline_9 Baseline_7 Baseline_8 Shock_13 Shock_12 Shock_15 Shock_22 Shock_14 Shock_16 Shock_2 Shock_3 Shock_7 Shock_4 Shock_8 Shock_9 Res_NS_14 Res_NS_13 Res_NS_16 Res_NS_12 Res_NS_22 Res_NS_15 Res_PFP_2 Res_PFP_3 Res_PFP_7 Res_PFP_4 Res_PFP_8 Res_PFP_9 Annotation-1 Annotation-1 Annotation Annotation-1 L-Arginine Aminoacids L-Isoleucine Aminoacids Leucine Aminoacids L-Cysteine Aminoacids L-Alanine Aminoacids L-Aspartate Aminoacids L-Glutamate Aminoacids L-Glutamine Aminoacids L-Histidine Aminoacids L-Lysine Aminoacids L-Methionine Aminoacids L-Tyrosine Aminoacids L-Asparagine Aminoacids L-Threonine Aminoacids L-Cystine Aminoacids L-Serine Aminoacids L-Proline Aminoacids L-Valine Aminoacids L-Tryptophan Aminoacids Glycine Aminoacids L-Kynurenine Aminoacids L-Phenylalanine Aminoacids CMP Nucleotides 6-Hydroxynicotinate Nucleotides 5-6-Dihydrouracil Nucleotides AMP Nucleotides dAMP Nucleotides GMP Nucleotides Guanine Nucleotides 2-5-Dihydroxypyridine -
35 Disorders of Purine and Pyrimidine Metabolism
35 Disorders of Purine and Pyrimidine Metabolism Georges van den Berghe, M.- Françoise Vincent, Sandrine Marie 35.1 Inborn Errors of Purine Metabolism – 435 35.1.1 Phosphoribosyl Pyrophosphate Synthetase Superactivity – 435 35.1.2 Adenylosuccinase Deficiency – 436 35.1.3 AICA-Ribosiduria – 437 35.1.4 Muscle AMP Deaminase Deficiency – 437 35.1.5 Adenosine Deaminase Deficiency – 438 35.1.6 Adenosine Deaminase Superactivity – 439 35.1.7 Purine Nucleoside Phosphorylase Deficiency – 440 35.1.8 Xanthine Oxidase Deficiency – 440 35.1.9 Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency – 441 35.1.10 Adenine Phosphoribosyltransferase Deficiency – 442 35.1.11 Deoxyguanosine Kinase Deficiency – 442 35.2 Inborn Errors of Pyrimidine Metabolism – 445 35.2.1 UMP Synthase Deficiency (Hereditary Orotic Aciduria) – 445 35.2.2 Dihydropyrimidine Dehydrogenase Deficiency – 445 35.2.3 Dihydropyrimidinase Deficiency – 446 35.2.4 Ureidopropionase Deficiency – 446 35.2.5 Pyrimidine 5’-Nucleotidase Deficiency – 446 35.2.6 Cytosolic 5’-Nucleotidase Superactivity – 447 35.2.7 Thymidine Phosphorylase Deficiency – 447 35.2.8 Thymidine Kinase Deficiency – 447 References – 447 434 Chapter 35 · Disorders of Purine and Pyrimidine Metabolism Purine Metabolism Purine nucleotides are essential cellular constituents 4 The catabolic pathway starts from GMP, IMP and which intervene in energy transfer, metabolic regula- AMP, and produces uric acid, a poorly soluble tion, and synthesis of DNA and RNA. Purine metabo- compound, which tends to crystallize once its lism can be divided into three pathways: plasma concentration surpasses 6.5–7 mg/dl (0.38– 4 The biosynthetic pathway, often termed de novo, 0.47 mmol/l). starts with the formation of phosphoribosyl pyro- 4 The salvage pathway utilizes the purine bases, gua- phosphate (PRPP) and leads to the synthesis of nine, hypoxanthine and adenine, which are pro- inosine monophosphate (IMP). -
Clinical Symptoms of Defects in Pyrimidine Metabolism
ClinicalClinical symptomssymptoms ofof DefectsDefects inin pyrimidinepyrimidine metabolismmetabolism Birgit Assmann Department of General Pediatrics Universtiy Children‘s Hospital Düsseldorf, Germany Overview • Biosynthesis: UMP Synthase • Degradation: –– PyrimidinePyrimidine 55‘‘--Nucleotidase(UMPNucleotidase(UMP--Hydrolase)Hydrolase) – [Thymidine-Phosphorylase, mitochondrial] –– DihydropyrimidineDihydropyrimidine DehydrogenaseDehydrogenase –– DihydropyrimidinaseDihydropyrimidinase –– UreidopropionaseUreidopropionase HCO3+gluNH2 carbamoyl-P orotic acid OMP OPRT UMP OD UMPS UMPSUMPS == uridinemonophosphateuridinemonophosphate synthasesynthase Bifunctional enzyme (one gene): a) Orotate phosphoribosyl transferase (OPRT) b) Orotidine decarboxylase (OD) UMPS deficiency • = Hereditary orotic aciduria Hallmarks:Hallmarks: - MegaloblasticMegaloblastic anemiaanemia inin infantsinfants >> IfIf untreateduntreated:: FailureFailure toto thrivethrive PsychomotorPsychomotor retardationretardation • Therapy: uridine (≥100-150 mg/kg/d) Defects of pyrimidine degradation • Pyrimidine 5‘-Nucleotidase deficiency - chronic hemolytic anemia + basophilic stippling of erythrocytes • Thymidine phosphorylase deficiency = MNGIE=Mitoch. NeuroGastroIntestinal Encephalomyopathy Mitochondrial disorder with elevatedelevated urinaryurinary thymidinethymidine excretionexcretion HCO3+gluNH2 carbamoyl-P orotic acid OMP TMP UMP UMPS thymidine cytosolic 5‘- uridine Thym. Nucleotidase phosphor ylase thymine uracil Pyrimidine 5‘-Nucleotidase- SuperactivitySuperactivity • Existence -
Forms of Hypoxanthine Or, Through Interconversions, Guanine Or Adenine
826 GENETICS: GOTS AND GOLLUB PROC. N. A. S. Summary.-The ribonucleic acids of isolated thymus nuclei can be separated into two distinct fractions, one of which probably represents ribonucleic acid of the nu- cleolus. Studies of the incorporation of orotic acid-6-C"4 and adenosine-8-C'4 into these RNA fractions in vitro show great differences in their metabolic activity and different susceptibilities to an inhibitor of RNA synthesis, the "nucleolar" RNA being by far the more active. It is a pleasure to acknowledge our indebtedness to Mr. Rudolf Meudt for his careful and expert technical assistance. * This research was supported in part by a grant (RG-4919 M&G) from the United States Public Health Service. I V. G. Allfrey, A. E. Mirsky, and S. Osawa, Nature, 176, 1042, 1955. 2 V. G. Allfrey, A. E. Mirsky, and S. Osawa, J. Gen. Physiol., 40, 451, 1957. 3 R. Logan and J. N. Davidson, Biochim. et Biophys. Acta, 24, 196, 1957. 4 S. Osawa, K. Takata, and Y. Hotta (in press). 6 J. M. Webb, J. Biol. Chem., 221, 635, 1956. 6 M. Bessis, in Traite de cytologie sanguine (Paris: Masson & Cie, 1954), p. 83. J. N. Davidson and R. M. S. Smellie. Biochem. J.. 52, 594, 1952. SEQUENTIAL BLOCKADE IN ADENINE BIOSYNTHESIS BY GENETIC LOSS OF AN APPARENT BIFUNCTIONAL DEACYLASE* By JOSEPH S. GOTS AND EDITH G. GOLLUB DEPARTMENT OF MICROBIOLOGY, SCHOOL OF MEDICINE, UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PENNSYLVANIA Communicated by D. Wright Wilson, July 3, 1957 Along the biosynthetic pathway to the purines of nucleic acids, inosinic acid occurs as a pivotal point in a bifurcation which leads to adenylic acid along one branch and to guanylic acid along the other: (B) r- Adenylic acid (AMP) (A) Inosinic acid (IMP) (C) L|_ * Guanylic acid (GMP) Bacterial mutations may result in genetic impairments at three locations with respect to the pivotal inosinic acid, thus yielding auxotrophs with three broad classes of nutritional response. -
Lc and Lc-Free Mass Spectrometry Applications in Non-Targeted Metabolomics for Disease Detection and Early Prediction
LC AND LC-FREE MASS SPECTROMETRY APPLICATIONS IN NON-TARGETED METABOLOMICS FOR DISEASE DETECTION AND EARLY PREDICTION A Dissertation Presented to The Academic Faculty by Xiaoling Zang In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the School of Chemistry and Biochemistry Georgia Institute of Technology August 2018 COPYRIGHT © 2018 BY XIAOLING ZANG LC AND LC-FREE MASS SPECTROMETRY APPLICATIONS IN NON-TARGETED METABOLOMICS FOR DISEASE DETECTION AND EARLY PREDICTION Approved by: Dr. Facundo M. Fernández, Advisor Dr. Ronghu Wu School of Chemistry and Biochemistry School of Chemistry and Biochemistry Georgia Institute of Technology Georgia Institute of Technology Dr. María E. Monge, Co-advisor Dr. Matthew Torres Centro de Investigaciones en School of Biology Bionanociencias (CIBION) Georgia Institute of Technology Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) Dr. Julia Kubanek Dr. Mark Styczynski School of Chemistry and Biochemistry School of Chemical and Biomolecular Georgia Institute of Technology Engineering Georgia Institute of Technology Date Approved: July 23, 2018 Never give up on what you really want to do. The person with big dreams is more powerful than one with all the facts. -Albert Einstein, The World as I See It1 ACKNOWLEDGEMENTS There are many people who have helped and supported me a lot during my 6-year Ph.D. life at Georgia Tech. First of all, I want to express my deepest gratitude to my advisor, Dr. Facundo M. Fernández, for his guidance, support, patience and encouragement during my whole Ph.D. study. Under his mentorship over the last 6 years, I have gained so much knowledge and experience in mass spectrometry and have grown to become more independent and capable in handling the research projects. -
Behavior of Activities of Thymidine Metabolizing Enzymes in Human Leukemia-Lymphoma Cells1
[CANCER RESEARCH 49. 1090-1094. March I, 1989] Behavior of Activities of Thymidine Metabolizing Enzymes in Human Leukemia-Lymphoma Cells1 Taiichi Shiotani, Yasuko Hashimoto, Terukazu Tanaka, and Shozo Irino First Department of Internal Medicine, Kagawa Medical School, Ikenobe, Miki, Kagawa, 761-07, Japan ABSTRACT 7). These observations indicate the importance of this catabolic enzyme for dThd utilization. Thymidylate, an important pre The behavior of the activities of thymidine metabolizing enzymes, cursor of DNA synthesis, also may be produced by the de novo dihydrothymine dehydrogenase (EC 1.3.1.2) and thymidine phosphoryl- pathway through dTMP synthase. The correlation between cell ase (EC 2.4.2.4) for thymidine degradation, thymidine kinase (EC proliferation and dThd kinase (3, 4, 6, 8, 9) or dTMP synthase 2.7.1.75) and thymidylate synthase (EC 2.1.1.45) for DNA synthesis, was elucidated in cytosolic extracts from normal human lymphocytes and (8, 10, 11) has been demonstrated. The enhanced capacity for 13 human leukemia-lymphoma cell lines. In the normal human lympho the salvage pathway in leukemia (12, 13) appears to limit the cytes, the activities of dihydrothymine dehydrogenase, thymidine phos- antitumor effectiveness of antimetabolites of de novo pyrimidine phorylase, thymidine kinase, and thymidylate synthase were 6.88, 796, biosynthesis. The enzymic capacities of the de novo and salvage 0.30, and 0.29 nmol/h/mg protein, respectively. In leukemia-lymphoma pathways and dThd catabolism have not been determined si cell lines, the activities of synthetic enzymes, thymidine kinase, and multaneously in human leukemia-lymphoma cells. Therefore, thymidylate synthase, increased two- to 79-fold and 22- to 407-fold of the elucidation of the behavior of the enzymic capacities in the the normal lymphocyte values. -
Possible Prediction of Adverse Reactions to Pyrimidine Chemotherapy from Urinary Pyrimidine Levels and a Case of Asymptomatic Adult Dihydropyrimidinuria1
Vol. 2, 1937-1 941, December 1996 Clinical Cancer Research 1937 Possible Prediction of Adverse Reactions to Pyrimidine Chemotherapy from Urinary Pyrimidine Levels and a Case of Asymptomatic Adult Dihydropyrimidinuria1 Katsuo Hayashi,2 Kiyoshi Kidouchi, INTRODUCTION Satoshi Sumi, Masashi Mizokami, Etsuro Onto, Pyrimidine chemotherapy agents such as 5-FU3 are used widely but can occasionally cause serious adverse reactions. In Kazunoni Kumada, Ryuzo Ueda, and pyrimidine metabolism, uracil and thymine are first converted to Yoshino Wada dihydropyrimidines (dihydrouracil and dihydrothymine) by Departments of Medicine [K. H., K. Ku.] and Pediatrics [K. Ki.], DPD and then are metabolized to 3-ureidopropionic acid and Nagoya City Higashi General Hospital, 2-23 Wakamizu 1-chome, 3-ureidoisobutyric acid, respectively, by dihydropyrimidinase. Chikusa-ku, Nagoya 464, Japan, and Department of Pediatrics [S. S., These compounds are converted subsequently into 3-alanine Y. W.] and Second Department of Medicine [M. M., E. 0., R. U.], Nagoya City University Medical School. Nagoya, Japan and -arninoisobutyric acid, respectively ( 1). Because about 80% of an administered dose of 5-FU is degraded by this pathway, there is a possibility of adverse reactions occurring as ABSTRACT a result of DPD or dihydrophrimidinase deficiency. The value of Deficiency of dihydropyrimidine dehydrogenase or di- measuring peripheral blood monocyte DPD activity before ad- hydropyrimidinase, enzymes that catalyze the breakdown of ministering 5-FU has been suggested in Western countries (2- pyrimidine chemotherapy agents such as 5-fluorouracil, 6), but DPD deficiency has not been reported in Japan. may cause serious adverse reactions to these agents. We Using a method that permits analysis of dihydrouracil and attempted to establish the reference range for urinary pyri- uracil in small volumes of urine, we previously screened Japa- midines in adults to detect individuals with abnormal py- nese infants for abnormalities of pyrimidine metabolism and rimidine metabolism. -
Purine Metabolism Regulates DNA Repair and Therapy Resistance in Glioblastoma
ARTICLE https://doi.org/10.1038/s41467-020-17512-x OPEN Purine metabolism regulates DNA repair and therapy resistance in glioblastoma Weihua Zhou1,14, Yangyang Yao1,2,14, Andrew J. Scott1,3,14, Kari Wilder-Romans1, Joseph J. Dresser1, Christian K. Werner 1, Hanshi Sun1, Drew Pratt4, Peter Sajjakulnukit 5, Shuang G. Zhao1, Mary Davis1, Barbara S. Nelson5, Christopher J. Halbrook5, Li Zhang5, Francesco Gatto 6, Yoshie Umemura3,7, Angela K. Walker8, Maureen Kachman 8, Jann N. Sarkaria 9, Jianping Xiong2, Meredith A. Morgan1,3, Alnawaz Rehemtualla1,3, Maria G. Castro 3,10,11, Pedro Lowenstein 3,10,11, Sriram Chandrasekaran 3,12, ✉ Theodore S. Lawrence1,3, Costas A. Lyssiotis 3,5,13 & Daniel R. Wahl 1,3 1234567890():,; Intratumoral genomic heterogeneity in glioblastoma (GBM) is a barrier to overcoming therapy resistance. Treatments that are effective independent of genotype are urgently needed. By correlating intracellular metabolite levels with radiation resistance across dozens of genomically-distinct models of GBM, we find that purine metabolites, especially guany- lates, strongly correlate with radiation resistance. Inhibiting GTP synthesis radiosensitizes GBM cells and patient-derived neurospheres by impairing DNA repair. Likewise, adminis- tration of exogenous purine nucleosides protects sensitive GBM models from radiation by promoting DNA repair. Neither modulating pyrimidine metabolism nor purine salvage has similar effects. An FDA-approved inhibitor of GTP synthesis potentiates the effects of radiation in flank and orthotopic patient-derived xenograft models of GBM. High expression of the rate-limiting enzyme of de novo GTP synthesis is associated with shorter survival in GBM patients. These findings indicate that inhibiting purine synthesis may be a promising strategy to overcome therapy resistance in this genomically heterogeneous disease. -
British Journal of Nutrition (2015), 113, 560–573 Doi:10.1017/S0007114514004000 Q the Authors 2015
Downloaded from British Journal of Nutrition (2015), 113, 560–573 doi:10.1017/S0007114514004000 q The Authors 2015 https://www.cambridge.org/core Absorption and intermediary metabolism of purines and pyrimidines in lactating dairy cows Charlotte Stentoft1*, Betina Amdisen Røjen2, Søren Krogh Jensen1, Niels B. Kristensen2, . IP address: Mogens Vestergaard1 and Mogens Larsen1 1Department of Animal Science, Aarhus University, Foulum, Blichers Alle´ 20, DK-8830 Tjele, Denmark 170.106.35.229 2Knowledge Centre for Agriculture, DK-8200 Aarhus N, Denmark (Submitted 23 June 2014 – Final revision received 27 October 2014 – Accepted 9 November 2014 – First published online 26 January 2015) , on 30 Sep 2021 at 08:56:31 Abstract About 20 % of ruminal microbial N in dairy cows derives from purines and pyrimidines; however, their intermediary metabolism and contribution to the overall N metabolism has sparsely been described. In the present study, the postprandial patterns of net portal-drained viscera (PDV) and hepatic metabolism were assessed to evaluate purine and pyrimidine N in dairy cows. Blood was sampled simul- taneously from four veins with eight hourly samples from four multi-catheterised Holstein cows. Quantification of twenty purines and pyrimidines was performed with HPLC–MS/MS, and net fluxes were estimated across the PDV, hepatic tissue and total splanchnic , subject to the Cambridge Core terms of use, available at tissue (TSP). Concentration differences between veins of fifteen purine and pyrimidine nucleosides (NS), bases (BS) and degradation products (DP) were different from zero (P#0·05), resulting in the net PDV releases of purine NS (0·33–1·3 mmol/h), purine BS (0·0023–0·018 mmol/h), purine DP (7·0–7·8 mmol/h), pyrimidine NS (0·30–2·8 mmol/h) and pyrimidine DP (0·047–0·77 mmol/h). -
A Fairy Chemical, Imidazole-4-Carboxamide, Is
www.nature.com/scientificreports OPEN A Fairy Chemical, Imidazole-4- carboxamide, is Produced on a Novel Purine Metabolic Pathway in Received: 25 September 2018 Accepted: 14 May 2019 Rice Published: xx xx xxxx Hirohide Takemura1, Jae-Hoon Choi 2,3, Nobuo Matsuzaki1, Yuki Taniguchi2, Jing Wu3, Hirofumi Hirai2,3, Reiko Motohashi2,3, Tomohiro Asakawa4, Kazutada Ikeuchi5, Makoto Inai6, Toshiyuki Kan6 & Hirokazu Kawagishi1,2,3 Rings or arcs of fungus-regulated plant growth occurring on the foor of woodlands and grasslands are commonly called “fairy rings”. Fairy chemicals, 2-azahypoxanthine (AHX), imidazole-4-carboxamide (ICA), and 2-aza-8-oxohypoxanthine (AOH), are plant growth regulators involved in the phenomenon. The endogeny and biosynthetic pathways of AHX and AOH in plants have already been proven, however, those of ICA have remained unclear. We developed a high-sensitivity detection method for FCs including ICA and the endogenous ICA was detected in some plants for the frst time. The quantitative analysis of the endogenous level of ICA in rice and Arabidopsis were performed using 13C-double labeled ICA. In addition, the incorporation experiment and enzyme assay using the labeled compound into rice and partially purifed fraction of rice indicated that ICA is biosynthesized from 5-aminoimidazole-4- carboxamide (AICA), a metabolite on the purine metabolic pathway. The relationship between ICA and AHX was also discussed based on quantitative analysis and gene expression analysis. “Fairy rings” is a phenomenon in which fruiting bodies of higher fungi occur afer turfgrass grows and/or dies in the form of rings1. Tese diameters vary from a few centimeters to more than 15 meters and it is also known as a disease of turfgrass all over the world2,3. -
The Therapeutic Targeting of Folate Receptor Alpha Positive Tumors
Wayne State University Wayne State University Dissertations 1-1-2015 The Therapeutic Targeting Of Folate Receptor Alpha Positive Tumors Via Folate Receptor Selective Novel 5- And 6- Substituted Pyrrolo [2,3-D]pyrimidine Antifolates" Shermaine Kimberly Mitchell-Ryan Wayne State University, Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations Part of the Molecular Biology Commons, Oncology Commons, and the Pharmacology Commons Recommended Citation Mitchell-Ryan, Shermaine Kimberly, "The Therapeutic Targeting Of Folate Receptor Alpha Positive Tumors Via Folate Receptor Selective Novel 5- And 6- Substituted Pyrrolo [2,3-D]pyrimidine Antifolates"" (2015). Wayne State University Dissertations. Paper 1155. This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. THE THERAPEUTIC TARGETING OF FOLATE RECPTOR ALPHA POSITIVE TUMORS VIA FOLATE RECEPTOR-SELECTIVE NOVEL 5-AND 6- SUBSTITUTED PYRROLO [2,3-D] PYRIMIDINE ANTIFOLATES by SHERMAINE KIMBERLY MITCHELL-RYAN DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan In partial fulfilment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2015 Major: CANCER BIOLOGY Approved By: ________________________________________ Advisor Date ________________________________________ ________________________________________ ________________________________________ ________________________________________ DEDICATION This dissertation is dedicated to Seamus Isaiah Ryan, my sun (son), my world and my very reason to press forward and claim every reward life has to offer. My sojourn through this process would not have been possible without the love, support and encouragement of my husband, Paul Seamus Ryan. Thank you for your steadfast devotion, patience and understanding. -
Taxonomic Variations in the Gut Microbiome of Gout Patients With
Méndez‑Salazar et al. Mol Med (2021) 27:50 https://doi.org/10.1186/s10020‑021‑00311‑5 Molecular Medicine RESEARCH ARTICLE Open Access Taxonomic variations in the gut microbiome of gout patients with and without tophi might have a functional impact on urate metabolism Eder Orlando Méndez‑Salazar1,2†, Janitzia Vázquez‑Mellado3, Carlos S. Casimiro‑Soriguer4,5, Joaquin Dopazo4,5,6,7, Cankut Çubuk8, Yessica Zamudio‑Cuevas9, Adriana Francisco‑Balderas9, Karina Martínez‑Flores9, Javier Fernández‑Torres9, Carlos Lozada‑Pérez10, Carlos Pineda11, Austreberto Sánchez‑González12, Luis H. Silveira13, Ana I. Burguete‑García14, Citlalli Orbe‑Orihuela14, Alfredo Lagunas‑Martínez14, Alonso Vazquez‑Gomez15, Alberto López‑Reyes16, Berenice Palacios‑González1* and Gabriela Angélica Martínez‑Nava9† Abstract Objective: To evaluate the taxonomic composition of the gut microbiome in gout patients with and without tophi formation, and predict bacterial functions that might have an impact on urate metabolism. Methods: Hypervariable V3–V4 regions of the bacterial 16S rRNA gene from fecal samples of gout patients with and without tophi (n 33 and n 25, respectively) were sequenced and compared to fecal samples from 53 healthy controls. We explored= predictive =functional profles using bioinformatics in order to identify diferences in taxonomy and metabolic pathways. Results: We identifed a microbiome characterized by the lowest richness and a higher abundance of Phascolarc- tobacterium, Bacteroides, Akkermansia, and Ruminococcus_gnavus_group genera in patients with gout without tophi when compared to controls. The Proteobacteria phylum and the Escherichia-Shigella genus were more abundant in patients with tophaceous gout than in controls. Fold change analysis detected nine genera enriched in healthy controls compared to gout groups (Bifdobacterium, Butyricicoccus, Oscillobacter, Ruminococcaceae_UCG_010, Lach- nospiraceae_ND2007_group, Haemophilus, Ruminococcus_1, Clostridium_sensu_stricto_1, and Ruminococcaceae_ UGC_013).